| Title |
Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, August 2004
|
| DOI | 10.1007/s00280-004-0825-y |
| Pubmed ID | |
| Authors |
Klaus Mross, Bernward Niemann, Ulrich Massing, Joachim Drevs, Clemens Unger, Rupinder Bhamra, Christine E. Swenson |
| Abstract |
Liposomal encapsulation of doxorubicin is designed to increase safety and tolerability by decreasing cardiac and gastrointestinal toxicity through decreased exposure of these tissues to doxorubicin, while effectively delivering drug to the tumor. We conducted an open-label phase I study to determine the pharmacokinetic profile of a single dose of liposome-encapsulated doxorubicin (Myocet) in patients with various solid tumors. Safety and tolerability were monitored. |
Mendeley readers
The data shown below were compiled from readership statistics for 124 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 2% |
| Lithuania | 1 | <1% |
| Denmark | 1 | <1% |
| Poland | 1 | <1% |
| Unknown | 118 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 26 | 21% |
| Student > Master | 25 | 20% |
| Student > Bachelor | 18 | 15% |
| Student > Ph. D. Student | 17 | 14% |
| Other | 7 | 6% |
| Other | 15 | 12% |
| Unknown | 16 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 27 | 22% |
| Agricultural and Biological Sciences | 22 | 18% |
| Medicine and Dentistry | 15 | 12% |
| Biochemistry, Genetics and Molecular Biology | 13 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 10% |
| Other | 11 | 9% |
| Unknown | 23 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 January 2019.
All research outputs
#7,856,604
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#688
of 2,501 outputs
Outputs of similar age
#19,738
of 59,506 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#10
of 16 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 59,506 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.